Research Paper Volume 16, Issue 15 pp 11513—11534
S100A9, as a potential predictor of prognosis and immunotherapy response for GBM, promotes the malignant progression of GBM cells and migration of M2 macrophages
Figure 7. S100A9 was an effective tool to predict the response of tumor patients to immune checkpoint inhibitors (ICIs). (A, B) Differential expression of immune stimulatory genes (A) and immune inhibitory genes (B) between high and low expression groups of S100A9. (C, D) The correlation between S100A9 and immune stimulatory genes (C) and immune inhibitory genes (D). (E) In the two glioma cohorts (GSE4412 and GSE53733), S100A9 can effectively predict patients’ responses to ICIs based on the TIED algorithm. (F) In the two independent melanoma immunotherapy cohorts (Gide2019 and Vanallen), S100A9 can effectively predict patients’ responses to ICIs. Abbreviations: PD: progressive disease; PR: partial response; SD: stable disease.